Horizon Pharma (NASDAQ:HZNP) received a $17.00 price target from research analysts at Cantor Fitzgerald in a research report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 13.45% from the company’s previous close.

HZNP has been the topic of several other reports. Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma and gave the company a “buy” rating in a research report on Sunday, September 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price objective on shares of Horizon Pharma in a research report on Sunday, October 22nd. ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. Cowen reaffirmed a “buy” rating on shares of Horizon Pharma in a research report on Thursday, September 28th. Finally, Goldman Sachs Group began coverage on Horizon Pharma in a research report on Thursday, September 28th. They set a “buy” rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $18.75.

Shares of Horizon Pharma (NASDAQ HZNP) traded down $0.40 during trading hours on Monday, reaching $14.99. The company had a trading volume of 697,591 shares, compared to its average volume of 1,548,983. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $18.31. The stock has a market cap of $2,480.00, a P/E ratio of -4.93, a PEG ratio of 0.73 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The business’s revenue was up 30.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.70 EPS. equities research analysts anticipate that Horizon Pharma will post 0.72 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of HZNP. Bank of Montreal Can boosted its position in shares of Horizon Pharma by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Horizon Pharma by 3.4% in the 2nd quarter. Rhumbline Advisers now owns 210,843 shares of the biopharmaceutical company’s stock worth $2,503,000 after purchasing an additional 6,871 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Horizon Pharma by 19.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock worth $10,866,000 after purchasing an additional 150,850 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Horizon Pharma by 4.2% in the 2nd quarter. Legal & General Group Plc now owns 56,552 shares of the biopharmaceutical company’s stock worth $669,000 after purchasing an additional 2,282 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Horizon Pharma by 432.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 49,988 shares of the biopharmaceutical company’s stock worth $593,000 after purchasing an additional 40,591 shares in the last quarter. 86.58% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-horizon-pharma-hznp-a-17-00-price-target/1801448.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.